Pure Relapsing Short Myelitis

Archive ouverte

Poullet, Zélia | Pique, Julie | Maarouf, Adil | Boutiere, Clemence | Rico, Audrey | Demortiere, Sarah | Durozard, Pierre | Papeix, Caroline | Maillart, Elisabeth | Collongues, Nicolas | Ayrignac, Xavier | Zephir, Helene | Deschamps, Romain | Ciron, Jonathan | Pelletier, Jean | Marignier, Romain | Audoin, Bertrand

Edité par CCSD ; American Academy of neurology -

International audience. Background and Objectives Pure relapsing short myelitis with clinical and paraclinical features suggesting multiple sclerosis (MS) has been described recently. Here, we evaluated the existence of this potential new form of MS by retrospectively searching for similar cases in the databases of the French tertiary MS centers. Methods Patients were included based on the present criteria: at least 2 short (<3 vertebral segments) myelitis episodes; minimum follow-up of 3 years; no MS-like brain lesion during all the followup; tested negative for both anti-myelin oligodendrocyte glycoprotein and anti-aquaporin 4 antibodies in serum; presence of oligoclonal bands in CSF; and comprehensive workup to exclude alternative diagnoses. Results Eighteen patients fulfilled all criteria. The sex ratio (females/males) was 5/1; the median (range) age at first relapse was 35.5 (25-54) years, the disease duration was 80.5 (50-308) months, and the annualized relapse rate was 0.36 (0.1-0.5). The median (range) number of relapses per patient was 2 (2-5), and the median (range) Expanded Disability Status Scale score at last follow-up was 1 (0-7.5). In CSF, the median (range) protein level was 0.34 g/L (0.18-0.77), and the median (range) number of mononuclear cells was 3 (0-28). Spinal cord MRI demonstrated a median (range) number of 2 (1-5) lesions per examination and 3 [1-7] on the last examination. Fifty-five percent of lesions involved the cervical levels. Secondary progressive evolution occurred in 3 of 18 (17%) patients. Discussion Pure spinal MS could be a rare entity in the MS disease spectrum. However, the existence of a distinct entity in the inflammatory CNS disorders cannot be excluded.

Suggestions

Du même auteur

Time to steroids impacts visual outcome of optic neuritis in MOGAD

Archive ouverte | Rode, Julie | CCSD

International audience. Background To characterise the response to treatment of inaugural optic neuritis (ON) in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Methods We sear...

TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis

Archive ouverte | Hilezian, Frédéric | CCSD

International audience. Objective To assess the efficacy of tumour necrosis factor-α (TNF-α) inhibitors used as steroid-sparing monotherapy in central nervous system (CNS) parenchymal sarcoidosis. Methods The French...

The long-term outcome of MOGAD: An observational national cohort study of 61 patients

Archive ouverte | Deschamps, Romain | CCSD

BACKGROUND AND OBJECTIVE: The prognosis in myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a matter of debate. Our aim was to assess the long-term outcomes of patients with MOGAD. METHODS: We retro...

Chargement des enrichissements...